Mission Therapeutics
4 known investors
Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis. It operates in the biotech and drug discovery field focused on DUB biology.
Investors · 4
Competitors · 2
by search overlapBioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Doximity5 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Companies competing with Mission Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Mission Therapeutics do?
- Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis. It operates in the biotech and drug discovery field focused on DUB biology.
- Who are Mission Therapeutics's investors?
- Mission Therapeutics's investors include Pfizer Venture Investments, Roche Venture Fund, Sofinnova Partners, SR One Capital Management.